Evaluate PBM exposure, prescription file value, DEA compliance, and staff retention risk before closing your pharmacy acquisition.
Find Pharmacy Acquisition TargetsAcquiring an independent pharmacy requires scrutiny beyond standard financials. Buyers must assess PBM reimbursement structures, DIR fee exposure, DEA and state board transferability, prescription file integrity, and staff licensing — all of which directly determine post-close profitability and continuity.
Validate true earnings by analyzing payer mix, DIR fees, and reimbursement trends. Normalize owner compensation and isolate non-recurring expenses to establish defensible EBITDA.
Review all PBM contracts for reimbursement rates, DIR fee clawback history, and preferred network eligibility. DIR fees can reduce net margins by 2–5% and must be modeled forward.
Compare tax returns to internal P&L statements across three years. Identify owner add-backs, above-market compensation, and any personal expenses run through the business.
Analyze AR aging from third-party payers, Medicare, and Medicaid. Receivables over 90 days may signal audit exposure or contract issues that reduce collectible value.
The prescription file is the pharmacy's core asset. Validate active patient count, refill rates, and revenue concentration to confirm the file supports the acquisition price.
Request a prescription file report showing active patients, refill rates, and drug category mix. Declining refill rates or patient counts over 24 months signal erosion in file value.
Identify revenue from compounding, long-term care, or specialty services. These segments carry higher margins and reduce dependency on low-margin generic PBM reimbursements.
Confirm how inventory is priced — typically at cost — and whether slow-moving or expired stock is excluded. Inventory is usually priced separately from the business purchase price.
Pharmacy acquisitions involve DEA registration transfers, state board approvals, and payer credentialing. Delays in any of these can prevent dispensing and create post-close revenue gaps.
Confirm the DEA registration and state pharmacy board license are current with no violations. Verify the transfer process timeline and whether a new DEA registration is required at closing.
Identify all licensed pharmacists and technicians, their credential status, and transition risk. A departing pharmacist-in-charge post-close can halt operations and trigger compliance issues.
Review the facility lease for assignment provisions and remaining term. A short lease or landlord refusal to assign can jeopardize the transaction or require costly renegotiation.
Most independent pharmacies sell at 3x–5.5x EBITDA, with prescription file value, specialty revenue mix, active patient count, and payer contract quality all influencing where a deal lands in that range.
DEA registrations are not transferable. The buyer must apply for a new DEA registration before dispensing controlled substances. This process can take 4–8 weeks and must be factored into closing timelines.
Yes. SBA 7(a) loans are commonly used for pharmacy acquisitions. Buyers typically finance 70–80% through SBA, with the seller carrying 10–20% via a seller note to bridge valuation gaps.
DIR fees are retroactive clawbacks from PBMs that reduce net reimbursement after dispensing. They are unpredictable, often disclosed months later, and can materially overstate reported pharmacy profitability if not modeled carefully.
More Pharmacy Guides
DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers